SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (537)6/4/2003 7:24:06 PM
From: Miljenko Zuanic  Read Replies (1) of 897
 
Tuck,

What can I tell you? Erik knows more about their management than I do. I was bit burned with OXGN, due to severe misleading. It was clear (in time) that CA4P has short therapeutic window and it will not have broad application, so BMY puled out. Now they are talking about di-phosphate derivative and fast track (for 500 pts)?

Well, maybe REGN can ask fast track status for Wilms tumor (+200 cases)?

RE short, I would first let fly as high as possible, than cut the wings. Today anything with angio- or cancer- prefix is HOT.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News